{"protocolSection":{"identificationModule":{"nctId":"NCT02444637","orgStudyIdInfo":{"id":"RACE_1.0"},"organization":{"fullName":"National Neuroscience Institute","class":"OTHER"},"briefTitle":"Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD","officialTitle":"Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage Alzheimer's Disease Having Coexisting Small Vessel Cerebrovascular Disease"},"statusModule":{"statusVerifiedDate":"2021-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-04","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-03","type":"ACTUAL"},"completionDateStruct":{"date":"2019-03","type":"ACTUAL"},"studyFirstSubmitDate":"2015-04-28","studyFirstSubmitQcDate":"2015-05-11","studyFirstPostDateStruct":{"date":"2015-05-14","type":"ESTIMATED"},"lastUpdateSubmitDate":"2021-03-03","lastUpdatePostDateStruct":{"date":"2021-03-05","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Dr Nagaendran Kandiah","investigatorTitle":"Senior Consultant, Department of Neurology","investigatorAffiliation":"National Neuroscience Institute"},"leadSponsor":{"name":"National Neuroscience Institute","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"Rivastigmine, an acetylcholinesterase inhibitor which has been approved by FDA \\& HSA, is authorized for use in the treatment of mild to moderate dementia of the Alzheimer's type.\n\nIn this trial, the investigators will be studying the effectiveness of Rivastigmine in subjects with AD and cerebrovascular disease."},"conditionsModule":{"conditions":["Alzheimer Disease","CVA (Cerebrovascular Accident)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":100,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Rivastigmine (Exelon) Patch","type":"EXPERIMENTAL","description":"For the first 4 weeks of the study, subjects will receive Rivastigmine patch 4.6mg/24 hours. Thereafter, subjects will receive Rivastigmine patch 9.5mg/24 hours.","interventionNames":["Drug: Rivastigmine"]}],"interventions":[{"type":"DRUG","name":"Rivastigmine","armGroupLabels":["Rivastigmine (Exelon) Patch"],"otherNames":["Exelon"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants with Demonstrated Benefit in Global and Cognitive Measures","timeFrame":"2 Years"}],"secondaryOutcomes":[{"measure":"Number of Participants with Adverse Events as a Measure of Safety and Tolerability","timeFrame":"2 Years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age between 50-85 years\n* Diagnosis of dementia of the Alzheimer's type according to the National Institute of Ageing-Alzheimer's Association Criteriah\n* MRI brain (with T2 or FLAIR sequences) performed within a 12 month period from time of recruitment demonstrating the presence of WMH of â‰¥2 on the Fazekas scale (Score range of 0-3 wherein a score of 1 indicates mild WMH, 2 indicates moderate WMH and 3 indicates severe WMH).i\n* Clinical Dementia Rating score of 1-2j\n* Mini-Mental State Examination (MMSE) scores of 12-26 inclusivek\n* English or Mandarin speaking, literate participants\n\nExclusion Criteria:\n\n* Severe neurological, psychiatric or systemic disease which in the opinion of the clinician could interfere with trial assessments\n* The use of any investigational drugs, new psychotropic or dopaminergic agents, cholinesterase inhibitors or anti-cholinergic agents during the 4 weeks prior to recruitment\n* Known skin allergy or previous allergic reaction to Rivastigmine patch","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"National Neuroscience Institute","city":"Singapore","zip":"308433","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000000544","term":"Alzheimer Disease"},{"id":"D000020521","term":"Stroke"}],"ancestors":[{"id":"D000003704","term":"Dementia"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000024801","term":"Tauopathies"},{"id":"D000019636","term":"Neurodegenerative Diseases"},{"id":"D000019965","term":"Neurocognitive Disorders"},{"id":"D000001523","term":"Mental Disorders"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"CVA (Cerebrovascular Accident)","relevance":"HIGH"},{"id":"M3575","name":"Alzheimer Disease","asFound":"Alzheimer's Disease","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M29127","name":"Cerebral Small Vessel Diseases","relevance":"LOW"},{"id":"M6594","name":"Dementia","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M22692","name":"Tauopathies","relevance":"LOW"},{"id":"M21248","name":"Neurodegenerative Diseases","relevance":"LOW"},{"id":"M21526","name":"Neurocognitive Disorders","relevance":"LOW"},{"id":"M4505","name":"Mental Disorders","relevance":"LOW"},{"id":"M14163","name":"Psychotic Disorders","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T2192","name":"Familial Alzheimer Disease","asFound":"Alzheimer's Disease","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BXM","name":"Behaviors and Mental Disorders"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068836","term":"Rivastigmine"}],"ancestors":[{"id":"D000002800","term":"Cholinesterase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018678","term":"Cholinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000018696","term":"Neuroprotective Agents"},{"id":"D000020011","term":"Protective Agents"}],"browseLeaves":[{"id":"M317","name":"Rivastigmine","asFound":"Nasopharyngeal Carcinoma","relevance":"HIGH"},{"id":"M5730","name":"Cholinesterase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M20448","name":"Cholinergic Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"},{"id":"M20463","name":"Neuroprotective Agents","relevance":"LOW"},{"id":"M21559","name":"Protective Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"NeuroAg","name":"Neuroprotective Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}